__timestamp | Exelixis, Inc. | Travere Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 2043000 | 570979 |
Thursday, January 1, 2015 | 3895000 | 2185000 |
Friday, January 1, 2016 | 6552000 | 4554000 |
Sunday, January 1, 2017 | 15066000 | 3605000 |
Monday, January 1, 2018 | 26348000 | 5527000 |
Tuesday, January 1, 2019 | 33097000 | 5234000 |
Wednesday, January 1, 2020 | 36272000 | 6126000 |
Friday, January 1, 2021 | 52873000 | 6784000 |
Saturday, January 1, 2022 | 57909000 | 7592000 |
Sunday, January 1, 2023 | 72547000 | 11450000 |
Cracking the code
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This chart provides a fascinating glimpse into the cost of revenue trends for Exelixis, Inc. and Travere Therapeutics, Inc. over the past decade. From 2014 to 2023, Exelixis, Inc. has seen a staggering increase in its cost of revenue, growing by over 3,400%, from approximately $2 million to $72 million. In contrast, Travere Therapeutics, Inc. experienced a more modest growth of around 1,900%, starting at $570,979 and reaching $11 million. This divergence highlights the varying operational scales and strategic investments of these companies. As Exelixis, Inc. continues to expand its market presence, Travere Therapeutics, Inc. is steadily increasing its cost efficiency. These trends offer valuable insights into the financial health and strategic directions of these biotech firms.
Cost of Revenue Comparison: Amgen Inc. vs Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Catalent, Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Sarepta Therapeutics, Inc. vs Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Walgreens Boots Alliance, Inc. vs Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Exelixis, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Comparison: Exelixis, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Xencor, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Dyne Therapeutics, Inc.'s Expenses